Search

Your search keyword '"Kelsen, David P."' showing total 608 results

Search Constraints

Start Over You searched for: Author "Kelsen, David P." Remove constraint Author: "Kelsen, David P."
608 results on '"Kelsen, David P."'

Search Results

1. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer

2. Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

3. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review.

5. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

7. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients

8. Optimization of ultracentrifugation‐based method to enhance the purity and proteomic profiling depth of plasma‐derived extracellular vesicles and particles.

9. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

10. Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages

12. Comprehensive molecular characterization of gastric adenocarcinoma

13. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

14. Pilot study of rapid MR pancreas screening for patients with BRCA mutation

15. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

16. Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer

19. Perioperative versus total neoadjuvant chemotherapy in gastric cancer

20. Data from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

21. Supplementary Figure Legends from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

22. Figure S1 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

23. Supplementary Figure Legends from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

24. Figure S2 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

25. Data from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

26. Supplementary Tables S1-S10 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

27. Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

28. Supplementary Figure from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

29. Supplementary Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

30. Data from Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer

31. Supplementary Data from Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer

32. Supplementary Figure Legends from Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

33. Supplementary Data from Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer

35. Supplementary from Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

37. Abstract C016: New treatment modality for pancreatic cancer-Vascular Targeted Photodynamic therapy with WST11 (Padeliporfin) combined with endovascular light delivery

39. Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

40. Integrated genomic characterization of oesophageal carcinoma

42. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer

43. PD-L1 expression and overall survival in Asian and western patients with gastric cancer

46. Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer

47. Tumour extracellular vesicles and particles induce liver metabolic dysfunction

Catalog

Books, media, physical & digital resources